{"preliminary_commentary":{"by_channel":{"youtube":8,"x_thread":7,"podcast":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03789110\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["nivolumab","ipilimumab"]],"indication":"hypermutated HER2-negative metastatic breast cancer","name":"NIMBUS","nct_id":"NCT03789110","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nimbus-nct03789110. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"* Ipilimumab is administered intravenously every 6 weeks\n* Nivolumab is administered intravenously every 2 weeks","label":"Nivolumab+Ipilimumab","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2027-02-28","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":30,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab","otherNames":["Opdivo"],"type":"DRUG"},{"name":"Ipilimumab","otherNames":["Yervoy"],"type":"DRUG"}],"last_update":"2026-04-28","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2021-09-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Response Rate of Nivolumab in Combination With Ipilimumab","timeFrame":"2 years"}],"references":[{"citation":"Barroso-Sousa R, Zanudo JGT, Li T, Reddy SM, Emens LA, Kuntz TM, Silva CAC, AlDubayan SH, Chu H, Overmoyer B, Lange P, DiLullo MK, Montesion M, Kasparian J, Hughes ME, Attaya V, Basta A, Lin NU, Tayob N, Jeselsohn R, Mittendorf EA, Tolaney SM. Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS). Nat Commun. 2025 May 13;16(1):4430. doi: 10.1038/s41467-025-59695-1.","pmid":"40360544","type":"DERIVED"}],"start_date":{"date":"2019-03-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer","url":"https://clinicaltrials.gov/study/NCT03789110"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nimbus-nct03789110"}